<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04583111</url>
  </required_header>
  <id_info>
    <org_study_id>RJYYXHNK-006</org_study_id>
    <nct_id>NCT04583111</nct_id>
  </id_info>
  <brief_title>The Effect of Antiemetics on Bowel Preparation Before Colonoscopy</brief_title>
  <official_title>The Effect of Antiemetics on Bowel Preparation Before Colonoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polyethylene glycol (PEG) is one of the most common laxatives used in colonoscopy. However, 5&#xD;
      - 15% of patients can not complete the preparation due to its poor taste and large volume. So&#xD;
      this study is aimed to explore the effect of antiemetics on abdominal discomforts associated&#xD;
      with PEG.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of the discomforts during bowel preparation</measure>
    <time_frame>before colonoscopy</time_frame>
    <description>The primary endpoint of this study was the discomforts during bowel preparation such as nausea, vomit, abdominal fullness and pain. These symptoms were assessed as none, mild, moderate and severe. Patients with mild to severe symptoms were classified as presence of discomforts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The quality of bowel preparation assessed by Boston Bowel Preparation Scale</measure>
    <time_frame>during colonoscopy</time_frame>
    <description>The secondary endpoint was the quality of bowel preparation assessed by the Boston Bowel Preparation Scale (BBPS) during the withdrawal phase of colonoscopy. The BBPS uses a 0-3 points scale assessing the bowel preparation quality in 3 segments of the colon (the right, transverse and left colons). BBPS score â‰¥ 6 were defined as adequate bowel preparation.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Bowel Preparation</condition>
  <arm_group>
    <arm_group_label>Domperidone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in Domperidone group took 10mg of domperidone 30min before PEG.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sulpiride group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in Sulpiride group took 100mg of sulpiride 30min before PEG.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in Control group followed the regular routine of 3L split-dose of PEG.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Domperidone</intervention_name>
    <description>Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.</description>
    <arm_group_label>Domperidone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sulpiride</intervention_name>
    <description>Domperidone and sulpiride are antiemetics that may be useful in preventing the PEG-related nausea and vomiting.</description>
    <arm_group_label>Sulpiride group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-70 years patients scheduled for colonoscopy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  intestinal obstruction or hemorrhage;&#xD;
&#xD;
          -  allergy to domperidone, sulpiride or PEG;&#xD;
&#xD;
          -  pregnancy or breastfeeding;&#xD;
&#xD;
          -  previous use of prokinetics within 1 month.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shengliang Chen, Dr</last_name>
    <phone>02158752345</phone>
    <email>slchenmd@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shengliang Chen</name>
      <address>
        <city>Shanghai</city>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shengliang Chen</last_name>
      <phone>02158752345</phone>
      <email>chenslmd@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2020</study_first_posted>
  <last_update_submitted>October 4, 2020</last_update_submitted>
  <last_update_submitted_qc>October 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RenJi Hospital</investigator_affiliation>
    <investigator_full_name>Shengliang Chen</investigator_full_name>
    <investigator_title>Deputy director of the Division of Gastroenterology and Hepatology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Domperidone</mesh_term>
    <mesh_term>Sulpiride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

